RxDoctor Payments Data

Luis Colon, MD

Ophthalmology · Indianapollis, INNPI 1255391686

Payments from drug & device makers

$3,917in general payments, 2019–2025

Across 103 payments — averaging $38.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$788
  • Lensar, Inc.$512
  • Glaukos Corporation$418
  • Bausch & Lomb Americas Inc.$350
  • Oyster Point Pharma, Inc.$254
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$244
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,917 in reported general payments places this provider in the 75th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$231,279
Medicare patients
510
Services billed
2,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost70$43,596
RestasisCyclosporine32$36,962
VyzultaLatanoprostene Bunod53$28,873
TyrvayaVarenicline Tartrate30$24,721
XiidraLifitegrast19$19,994
Prednisolone Acetate264$12,066
RocklatanNetarsudil Mesylat/Latanoprost14$9,609
Fluorometholone122$9,275
SimbrinzaBrinzolamide/Brimonidine Tart23$7,510
Travoprost43$7,321
TafluprostTafluprost/Pf24$7,024
Ketorolac Tromethamine201$5,706
RhopressaNetarsudil Mesylate14$5,168
Loteprednol Etabonate24$5,078
CombiganBrimonidine Tartrate/Timolol16$5,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$788$85,619118 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$350$48,86772 claims
Oyster Point Pharma, Inc.Tyrvaya$254$24,72130 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$24$14,77728 claims
AlconSimbrinza$140$7,51023 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$244$5,07824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Indianapollis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →